Young Matthew P. 4

What Happened

• Matthew P. Young, a director of CytomX Therapeutics (CTMX), was granted a derivative award covering 59,000 shares on 2026-06-17. The filing reports a $0.00 price (no cash paid at grant) and classifies the transaction as an award/grant (code A).
• This award is described in the filing as an option-type award that will vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the 2027 annual meeting of stockholders, provided Young remains a director through the vesting date (footnote F1).

Key Details

• Transaction date: 2026-06-17; Form 4 filed: 2026-06-22.
• Reported price: $0.00 per share; total reported cash paid: $0.
• Amount: 59,000 derivative shares (option-style award per footnote).
• Shares owned after transaction: not specified in the provided filing.
• Vesting: 100% vests on earlier of one year from grant or the 2027 annual meeting, subject to continued service (footnote F1).
• Timeliness: Filing was submitted five days after the transaction date (appears late for the usual Section 16 two-business-day rule).

Context

• This was a director compensation award (a derivative grant), not an open-market purchase or sale. Such grants are common for board service and do not necessarily indicate personal bullishness or immediate liquidity events.
• Because it’s a derivative award with a vesting condition, there was no immediate sale or cash received by the director at grant.